Emergent Current Deferred Revenue from 2010 to 2024
| EBS Stock | USD 10.11 0.08 0.80% |
Current Deferred Revenue | First Reported 2004-12-31 | Previous Quarter 5.5 M | Current Value 6.2 M | Quarterly Volatility 37.3 M |
Check Emergent Biosolutions financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Emergent Biosolutions' main balance sheet or income statement drivers, such as Depreciation And Amortization of 135.6 M, Interest Expense of 92.3 M or Total Revenue of 560.8 M, as well as many indicators such as Price To Sales Ratio of 0.11, Dividend Yield of 0.018 or PTB Ratio of 0.18. Emergent financial statements analysis is a perfect complement when working with Emergent Biosolutions Valuation or Volatility modules.
Emergent | Current Deferred Revenue |
Latest Emergent Biosolutions' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Emergent Biosolutions over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Emergent Biosolutions' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Emergent Biosolutions' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Emergent Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 35,072,848 | |
| Geometric Mean | 13,945,137 | |
| Coefficient Of Variation | 136.56 | |
| Mean Deviation | 35,810,861 | |
| Median | 13,232,000 | |
| Standard Deviation | 47,895,685 | |
| Sample Variance | 2294T | |
| Range | 139M | |
| R-Value | 0.50 | |
| Mean Square Error | 1860.4T | |
| R-Squared | 0.25 | |
| Significance | 0.06 | |
| Slope | 5,321,975 | |
| Total Sum of Squares | 32116T |
Emergent Current Deferred Revenue History
About Emergent Biosolutions Financial Statements
Emergent Biosolutions shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Emergent Biosolutions investors may analyze each financial statement separately, they are all interrelated. The changes in Emergent Biosolutions' assets and liabilities, for example, are also reflected in the revenues and expenses on on Emergent Biosolutions' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 30.4 M | 28.1 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.